Propanc Files Two More Patents Citing New Compositions Of Proenzymes For Cancer Treatment
Published: Apr 19, 2016
MELBOURNE, Australia, April 19, 2016 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the filing of two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer. The inventions summarize different combinations of the two proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance their anti-cancer effects, compared to when used in a one to one ratio, or as singular agents.
The combinations are in addition to the preferred combination for PRP, and supplements the Company's patent position across a broad range of cancers.
"When confirming PRP's effectiveness across a broad range of cancers, we also confirmed a synergistic response between the two proenzymes to the majority of cancer cell lines tested," said Dr Julian Kenyon, Propanc's Chief Scientific Officer. "We also noticed that for some cancer types, more than one combination proved to be effective, which we believe is patentable. This is extremely important, because it not only confirms the utility of our lead product, PRP, for many different cancers, but also enables us to incorporate other effective combinations as well. In total, we now have five individual patents covering PRP and also expect to file further divisional applications in various jurisdictions. We are extremely pleased with our progress as we develop a robust portfolio as leaders in the field."
"Dr Kenyon and our team of researchers have done an excellent job in continuing to grow and protect the Company's IP position," said James Nathanielsz, Propanc's Chief Executive Officer. "New, potentially patentable discoveries have also been made regarding the anti-cancer effects of proenzymes which we believe could have significant implications in the cancer treatment process. We look forward to continuing to build on this research. Furthermore, we are now preparing for what is a significant period for the Company as we turn our attention to the upcoming scientific advice meeting, preparing orphan drug designation applications and developing a strategy to engage licensing partners interested in our R&D programs, as we head towards early stage patient trials."
The Company is soon to meet with the MHRA (Medicines and Healthcare Products Regulatory Agency) to discuss formal preclinical and clinical development activities for PRP. Management also intends to apply for orphan drug designation for pancreatic and ovarian cancers in the US and EU in the near future as well, should they satisfy the necessary criteria.
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Certain of the matters discussed in this announcement involve risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary, to develop certain products, its ability to implement its long range business plan for various applications of its technology, and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/propanc-files-two-more-patents-citing-new-compositions-of-proenzymes-for-cancer-treatment-300253575.html
SOURCE Propanc Health Group Corporation